Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 861-870

  Gluz, Oleg ^a   Nitz, U A ^a   Harbeck, N ^b   Ting, E ^a   Kates, R ^b   Herr, A ^c   Lindemann, W ^d   Jackisch, C ^e   Berdel, W E ^f   Kirchner, H ^g   Metzner, B ^h   Werner, F ^a   Schutt G ^a   Frick, M ^a   Poremba, C ^a   Diallo Danebrock, R ^a   Mohrmann, S ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d Catholic Hospital   (Germany)

^e City Hospital   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g Siloah Clinic   (Germany)

^h KLINIKUM OLDENBURG   (Germany)

Author keywords

Basal like; Breast cancer; High dose chemotherapy; Triple negative

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; METHOTREXATE; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 43249092223     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm551     Document Type: Article

References (41)

1. B. Fisher M. Bauer D.L. Wickerham Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update Cancer 52 9 1983 1551 1557
2. A.J. Montero R. Rouzier A. Lluch The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study Cancer 104 2 2005 229 235
3. Early Breast Cancer Trialists' Collaborative Group and EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 1687 1717
4. A.U. Buzdar S.W. Kau G.N. Hortobagyi Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy Cancer 69 2 1992 448 452
5. S. Rodenhuis M. Bontenbal L.V. Beex High-dose chemotherapy with hematopoetic stem-cell rescue for high risk breast cancer N Engl J Med 349 1 2003 7 16
6. M.S. Tallman R. Gray N.J. Robert Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 349 1 2003 17 26
7. S. Rodenhuis M. Bontenbal Q.G. van Hoesel Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol 17 4 2006 588 596
8. H. Roche P. Viens P. Biron High-dose chemotherapy for breast cancer: the French PEGASE experience Cancer Control 10 1 2003 42 47
9. U. Nitz S. Mohrmann J. Fischer Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial Lancet 366 9501 2005 1935 1944
10. A.R. Zander N. Kroeger C. Schmoor High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial J Clin Oncol 22 12 2004 2273 2283
11. R.L. Basser A. O'Neill G. Martinelli Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95 J Clin Oncol 24 3 2006 370 378
12. R. Leonard M. Lind C. Twelves Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial J Natl Cancer Inst 96 14 2004 1076 1083
13. W. Peters G.L. Rosner J.J. Vredenburgh Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13 J Clin Oncol 23 10 2005 2191 2200
14. I.F. Faneyte J.L. Peterse H. Van Tinteren Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement Clin Cancer Res 10 13 2004 4457 4463
15. Y. Nieto S. Nawaz E.J. Shpall Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy Clin Cancer Res 10 8 2004 2609 2617
16. N. Kroger K. Milde-Langosch S. Riethdorf Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients Clin Cancer Res 12 1 2006 159 168
17. C.M. Perou T. Sorlie M.B. Eisen Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
18. R. Rouzier C.M. Perou W.F. Symmans Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 2005 5678 5685
19. M. Colleoni G. Viale D. Zahrieh Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 19 2004 6622 6628
20. D.A. Berry C. Cirrincione I.C. Henderson Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 14 2006 1658 1667
21. M. Venturini L. Del Mastro E. Aitini Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial J Natl Cancer Inst 97 23 2005 1724 1733
22. J. Bergh T. Wiklund B. Erikstein Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial Lancet 356 9239 2000 1384 1391
23. G. Somlo J.F. Simpson P. Frankel Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer Br J Cancer 87 3 2002 281 288
24. A.M. Gianni G. Bonadonna Updated 12-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+) Cooperative Group 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25 18 Suppl 2007 Abstr 549
25. J. Hannemann J. Hannemann P. Kristel Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy Br J Cancer 95 10 2006 1334 1341
26. R. Diallo-Danebrock E. Ting O. Gluz Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy Clin Cancer Res 13 2 2007 488 497
27. M. Tanner J. Isola T. Wiklund Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 16 2006 2428 2436
28. A.D. Thor D.A. Berry D.R. Budman erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 18 1998 1346 1360
29. S. Paik J. Bryant E. Tan-Chiu HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst 92 24 2000 1991 1998
30. Y. Nieto P.J. Cagnoni S. Nawaz Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation J Clin Oncol 18 10 2000 2070 2080
31. M. Hensel A. Schneeweiss H.P. Sinn P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support Int J Cancer 100 3 2002 290 296
32. A. Gennari M. Sormani M. Puntoni A pooled analysis on the interaction between HER-2 expression and responsiveness of breast cancer to adjuvant chemotherapy Breast Cancer Res Treat 100 Suppl 1 2006 (Abstr 41)
33. Y. Nieto J.J. Vredenburgh E.J. Shpall Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer Clin Cancer Res 10 21 2004 7136 7143
34. T. Sorlie R. Tibshirani J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 14 2003 8418 8423
35. L.A. Carey E.C. Dees L. Sawyer The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2007 2329 2334
36. S.R. Lakhani M.J. Van De Vijver J. Jacquemier The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 9 2002 2310 2318
37. M.J. Kandel Z. Stadler S. Masciari Prevalence of BRCA1 mutations in triple negative breast cancer (BC) Proceedings of the Annual Meeting of American Society of Clinical Oncology 24 18 Suppl 2006 (Abstr 508)
38. R.D. Kennedy J.E. Quinn P.B. Mullan The role of BRCA1 in the cellular response to chemotherapy J Natl Cancer Inst 96 22 2004 1659 1668
39. E. Rakha M. El-Sayed A. Green Prognostic markers in triple-negative breast cancer Cancer 109 1 2007 25 32
40. R.I. Nicholson J.M. Gee M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 2001 S9 S15
41. F. Huang K. Reeves X. Han Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection Cancer Res 67 5 2007 2226 2238